XNAS
AXDX
Market cap952kUSD
May 14, Last price
0.03USD
Name
Accelerate Diagnostics Inc
Chart & Performance
Profile
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 11,698 -2.99% | 12,059 -5.43% | 12,752 8.23% | |||||||
Cost of revenue | 25,682 | 34,862 | 36,364 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (13,984) | (22,803) | (23,612) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (66) | 850 | (77) | |||||||
Tax Rate | ||||||||||
NOPAT | (13,918) | (23,653) | (23,535) | |||||||
Net income | (50,045) -18.78% | (61,618) -1.40% | (62,493) -19.57% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 29,982 | 4,000 | 33,320 | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 16,512 | 2,286 | 58,355 | |||||||
Long-term debt | 50,064 | 39,326 | 23,454 | |||||||
Deferred revenue | 1,122 | |||||||||
Other long-term liabilities | 6,556 | 1,164 | 1,537 | |||||||
Net debt | 51,478 | 28,393 | 36,248 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (24,194) | (40,196) | (48,728) | |||||||
CAPEX | (1,035) | (554) | ||||||||
Cash from investing activities | (509) | 8,660 | 12,417 | |||||||
Cash from financing activities | 27,053 | 9,019 | 31,630 | |||||||
FCF | (13,153) | (21,044) | (22,079) | |||||||
Balance | ||||||||||
Cash | 15,098 | 13,219 | 45,561 | |||||||
Long term investments | ||||||||||
Excess cash | 14,513 | 12,616 | 44,923 | |||||||
Stockholders' equity | (6) | (669,455) | (607,538) | |||||||
Invested Capital | 13,873 | 691,073 | 664,351 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 23,302 | 12,477 | 8,216 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (10,563) | (19,549) | (20,612) | |||||||
EV/EBITDA | ||||||||||
Interest | 13,117 | 7,743 | 3,771 | |||||||
Interest/NOPBT |